It really sucks to be a type-1 diabetic in this world. Every time a company comes up with a newer way to take our insulin by means other than injection, the idea gets tossed aside for some reason or another.
Eli Lilly has decided that there is not enough commercial potential in the manufacture of inhaled insulin to continue pursuing the treatment option. I think that means that the corporate big-boys have decided that they can't make enough money off of the inhaled product, so let's drop it.
Indianapolis-based Lilly said its decision was not based on safety concerns, "but rather was a result of increasing uncertainties in the regulatory environment, and a thorough evaluation of the evolving commercial and clinical potential of the product compared to existing medical therapies."
I guess that selling syringes, insulin in vials, and pumps are a more profitable course for the company. I was looking forward to being able to use this type of insulin. Oh well! I hope that Lilly's competitors are working on this.
0 Comments:
Post a Comment